A proof of concept study of HLD-400 as potential therapy for inflammatory bowel disease using scintigraphy imaging

Trial Profile

A proof of concept study of HLD-400 as potential therapy for inflammatory bowel disease using scintigraphy imaging

Planning
Phase of Trial: Phase I

Latest Information Update: 30 May 2016

At a glance

  • Drugs HLD 400 (Primary)
  • Indications Inflammatory bowel diseases
  • Focus Pharmacodynamics; Pharmacokinetics; Proof of concept
  • Most Recent Events

    • 30 May 2016 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top